CSL Ltd (CSL) - Total Assets
Based on the latest financial reports, CSL Ltd (CSL) holds total assets worth AU$39.54 Billion AUD (≈ $27.98 Billion USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can CSL Ltd service its debt to assess how comfortably operating cash covers total debt obligations.
CSL Ltd - Total Assets Trend (1993–2025)
This chart illustrates how CSL Ltd's total assets have evolved over time, based on quarterly financial data. See net assets of CSL Ltd for net asset value and shareholders' equity analysis.
CSL Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
CSL Ltd's total assets of AU$39.54 Billion consist of 30.1% current assets and 69.9% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 5.5% |
| Accounts Receivable | AU$2.88 Billion | 7.3% |
| Inventory | AU$6.47 Billion | 16.4% |
| Property, Plant & Equipment | AU$9.80 Billion | 24.9% |
| Intangible Assets | AU$8.12 Billion | 20.6% |
| Goodwill | AU$8.06 Billion | 20.5% |
Asset Composition Trend (1993–2025)
This chart illustrates how CSL Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CSL market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CSL Ltd's current assets represent 30.1% of total assets in 2025, a decrease from 46.3% in 1993.
- Cash Position: Cash and equivalents constituted 5.5% of total assets in 2025, up from 2.8% in 1993.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 40.0% of total assets, an increase from 1.0% in 1993.
- Asset Diversification: The largest asset category is property, plant & equipment at 24.9% of total assets.
CSL Ltd Competitors by Total Assets
Key competitors of CSL Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
USA | $949.87 Million |
|
Sk Biopharmaceuticals Co Ltd
KO:326030
|
Korea | ₩1.20 Trillion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
CSL Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.46 | 2.18 | 3.01 |
| Quick Ratio | 1.12 | 0.97 | 1.37 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$7.06 Billion | AU$5.82 Billion | AU$4.30 Billion |
CSL Ltd - Advanced Valuation Insights
This section examines the relationship between CSL Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.17 |
| Latest Market Cap to Assets Ratio | 1.03 |
| Asset Growth Rate (YoY) | 3.6% |
| Total Assets | AU$39.40 Billion |
| Market Capitalization | $40.49 Billion USD |
Valuation Analysis
Above Book Valuation: The market values CSL Ltd's assets above their book value (1.03x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: CSL Ltd's assets grew by 3.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for CSL Ltd (1993–2025)
The table below shows the annual total assets of CSL Ltd from 1993 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$39.40 Billion ≈ $27.88 Billion |
+3.63% |
| 2024-06-30 | AU$38.02 Billion ≈ $26.90 Billion |
-30.15% |
| 2023-06-30 | AU$54.43 Billion ≈ $38.52 Billion |
+32.05% |
| 2022-06-30 | AU$41.22 Billion ≈ $29.17 Billion |
+127.02% |
| 2021-06-30 | AU$18.16 Billion ≈ $12.85 Billion |
+17.42% |
| 2020-06-30 | AU$15.46 Billion ≈ $10.94 Billion |
+26.07% |
| 2019-06-30 | AU$12.27 Billion ≈ $8.68 Billion |
+14.28% |
| 2018-06-30 | AU$10.73 Billion ≈ $7.60 Billion |
+17.66% |
| 2017-06-30 | AU$9.12 Billion ≈ $6.45 Billion |
+20.39% |
| 2016-06-30 | AU$7.58 Billion ≈ $5.36 Billion |
+55.68% |
| 2015-06-30 | AU$4.87 Billion ≈ $3.44 Billion |
-22.46% |
| 2014-06-30 | AU$6.28 Billion ≈ $4.44 Billion |
+5.06% |
| 2013-06-30 | AU$5.98 Billion ≈ $4.23 Billion |
-0.83% |
| 2012-06-30 | AU$6.03 Billion ≈ $4.26 Billion |
+4.01% |
| 2011-06-30 | AU$5.79 Billion ≈ $4.10 Billion |
+41.62% |
| 2010-06-30 | AU$4.09 Billion ≈ $2.89 Billion |
-13.94% |
| 2009-06-30 | AU$4.75 Billion ≈ $3.36 Billion |
+5.81% |
| 2008-06-30 | AU$4.49 Billion ≈ $3.18 Billion |
+48.79% |
| 2007-06-30 | AU$3.02 Billion ≈ $2.14 Billion |
+31.67% |
| 2006-06-30 | AU$2.29 Billion ≈ $1.62 Billion |
+2.48% |
| 2005-06-30 | AU$2.24 Billion ≈ $1.58 Billion |
-17.43% |
| 2004-06-30 | AU$2.71 Billion ≈ $1.92 Billion |
+166.85% |
| 2003-06-30 | AU$1.02 Billion ≈ $718.44 Million |
-22.00% |
| 2002-06-30 | AU$1.30 Billion ≈ $921.05 Million |
+180.08% |
| 2001-06-30 | AU$464.77 Million ≈ $328.86 Million |
+37.04% |
| 2000-06-30 | AU$339.16 Million ≈ $239.98 Million |
+36.06% |
| 1999-06-30 | AU$249.27 Million ≈ $176.37 Million |
+24.21% |
| 1998-06-30 | AU$200.68 Million ≈ $142.00 Million |
-47.90% |
| 1997-06-30 | AU$385.18 Million ≈ $272.54 Million |
+30.58% |
| 1996-06-30 | AU$294.99 Million ≈ $208.72 Million |
+23.38% |
| 1995-06-30 | AU$239.09 Million ≈ $169.17 Million |
-23.53% |
| 1994-06-30 | AU$312.67 Million ≈ $221.24 Million |
+204.58% |
| 1993-06-30 | AU$102.66 Million ≈ $72.64 Million |
-- |
About CSL Ltd
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma produ… Read more